A Phase 3 interventional study of Tegoprazan and RAPAE01 in Helicobacter Pylori Infection, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-12.
Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to compare safety and efficacy in an exploratory manner between a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.
A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.
HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tegoprazan 50 mg Triple Therapy
Drug: Tegoprazan
Tegoprazan 100 mg Triple Therapy
Drug: Tegoprazan
RAPAE01 Triple Therapy
Drug: RAPAE01
Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral
RAPAE01/Clarithromycin/Amoxicillin BID peroral
H. pylori eradication rate
Assess H. pylori eradication rate by UBT
Time frame: Day 49
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Dec 2020, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprazan